Una conferencia de amnesia. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Una conferencia de amnesia. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Common Factor. 1995 Apr;(no 10):30. Unique Identifier : AIDSLINE AIDS/95700380
Haas GJ

Abstract: The World Federation of Hemophilia held its 21st international meeting in Mexico City in April 1995. The crisis in current hemophilia care in developing countries is described as pathetic. One study reveals that countries not importing blood products or concentrates from the U.S. had little or no HIV transmission to persons with hemophilia, but many people were condemned to painful joint destruction. Numerous pharmaceutical, agricultural, and other companies have been caught dumping their substandard products overseas to avoid waste. The author suggests that if the fractitioners were to increase their production rate (which they could easily do), there would be enough recombinant factor concentrates to fully supply everyone in the U.S., as well as the rest of the world, at an even lower price than the intermediate-purity concentrates. Dumping inferior medical products into developing countries is viewed as irresponsible behavior. Further, the author contends that trust in the good intentions of the pharmaceutical industry, and the ability of the Federal regulatory structure, led to the ongoing death toll that the hemophilia community is now experiencing.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/TRANSMISSION Blood-Borne Pathogens Clinical Trials Commerce Developing Countries Drug Industry Factor IX/THERAPEUTIC USE Factor VIII/THERAPEUTIC USE Hemophilia/*COMPLICATIONS/THERAPY Human HIV Infections/*COMPLICATIONS/TRANSMISSION Recombinant Proteins/THERAPEUTIC USE United States NEWSLETTER ARTICLE

951130
M95B0886

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .